Microbial Pathogenesis,
Journal Year:
2024,
Volume and Issue:
197, P. 107091 - 107091
Published: Oct. 30, 2024
The
discoveries
of
the
oncomicrobiome
(intratumoral
microbiome)
and
oncomicrobiota
microbiota)
represent
significant
advances
in
tumor
research
have
rapidly
become
key
interest
to
field.
Within
tumors,
microorganisms
such
as
bacteria,
fungi,
viruses,
archaea
form
are
primarily
found
within
cells,
immunocytes,
intercellular
matrix.
exhibits
marked
heterogeneity
is
associated
with
initiation,
progression,
metastasis,
treatment
response.
Interactions
between
immune
system
can
modulate
host
antitumor
immunity,
influencing
efficacy
immunotherapies.
Oncomicrobiome
also
faces
numerous
challenges,
including
overcoming
methodological
issues
low
target
abundance,
susceptibility
contamination,
biases
sample
handling
analysis
methods
across
different
studies.
Furthermore,
studies
may
be
confounded
by
baseline
differences
microbiomes
among
populations
driven
both
environmental
genetic
factors.
Most
date
revealed
associations
but
very
few
established
mechanistic
links
two.
This
review
introduces
relevant
concepts,
detection
methods,
sources,
characteristics
oncomicrobiome.
We
then
describe
composition
common
tumors
its
role
shaping
microenvironment.
discuss
current
problems
challenges
overcome
this
progressing
Molecular Medicine,
Journal Year:
2025,
Volume and Issue:
31(1)
Published: March 18, 2025
Abstract
Pancreatic
cancer,
one
of
the
most
lethal
malignancies,
remains
challenging
due
to
late
diagnosis,
aggressive
progression,
and
therapeutic
resistance.
Recent
advances
have
revealed
presence
intratumoral
microbiota,
predominantly
originating
from
oral
gut
microbiomes,
which
play
pivotal
roles
in
pancreatic
cancer
pathogenesis.
The
dynamic
interplay
between
microbial
communities,
termed
“oral-gut
microbiota
axis,”
contributes
multifacetedly
ductal
adenocarcinoma
(PDAC).
Microbial
translocation
via
anatomical
or
circulatory
routes
establishes
tumor-resident
driving
oncogenesis
through
metabolic
reprogramming,
immune
regulation,
inhibition
apoptosis,
chronic
inflammation,
dysregulation
cell
cycle.
Additionally,
promote
chemoresistance
evasion,
further
complicating
treatment
outcomes.
Emerging
evidence
highlights
signatures
saliva
fecal
samples
as
promising
non-invasive
diagnostic
biomarkers,
while
diversity
correlates
with
prognosis.
Therapeutic
strategies
targeting
this
axis—such
antibiotics,
probiotics,
engineered
bacteria—demonstrate
potential
enhance
efficacy.
By
integrating
mechanisms
influence
on
tumor
biology,
drug
resistance,
applications,
oral-gut
axis
emerges
a
critical
regulator
PDAC,
offering
novel
perspectives
for
early
detection,
prognostic
assessment,
microbiome-based
interventions.
MedComm,
Journal Year:
2025,
Volume and Issue:
6(4)
Published: March 30, 2025
ABSTRACT
Signal
transducer
and
activator
of
transcription
3
(STAT3)
is
a
critical
factor
involved
in
multiple
physiological
pathological
processes.
While
STAT3
plays
an
essential
role
homeostasis,
its
persistent
activation
has
been
implicated
the
pathogenesis
various
diseases,
particularly
cancer,
bone‐related
autoimmune
disorders,
inflammatory
cardiovascular
neurodegenerative
conditions.
The
interleukin‐6/Janus
kinase
(JAK)/STAT3
signaling
axis
central
to
activation,
influencing
tumor
microenvironment
remodeling,
angiogenesis,
immune
evasion,
therapy
resistance.
Despite
extensive
research,
precise
mechanisms
underlying
dysregulated
disease
progression
remain
incompletely
understood,
no
United
States
Food
Drug
Administration
(USFDA)‐approved
direct
inhibitors
currently
exist.
This
review
provides
comprehensive
evaluation
STAT3's
health
disease,
emphasizing
involvement
cancer
stem
cell
maintenance,
metastasis,
inflammation,
drug
We
systematically
discuss
therapeutic
strategies,
including
JAK
(tofacitinib,
ruxolitinib),
Src
Homology
2
domain
(S3I‐201,
STATTIC),
antisense
oligonucleotides
(AZD9150),
nanomedicine‐based
delivery
systems,
which
enhance
specificity
bioavailability
while
reducing
toxicity.
By
integrating
molecular
mechanisms,
pathology,
emerging
interventions,
this
fills
knowledge
gap
STAT3‐targeted
therapy.
Our
insights
into
crosstalk,
epigenetic
regulation,
resistance
offer
foundation
for
developing
next‐generation
with
greater
clinical
efficacy
translational
potential.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(12), P. 10203 - 10203
Published: June 15, 2023
One
of
the
most
common
and
deadly
types
pancreatic
cancer
(PC)
is
ductal
adenocarcinoma
(PDAC),
with
patients
succumbing
to
disease
within
one
year
diagnosis.
Current
detection
strategies
do
not
address
asymptomatic
PC;
therefore,
are
diagnosed
at
an
advanced
stage
when
curative
treatment
often
no
longer
possible.
In
order
detect
PC
in
earlier,
risk
factors
that
could
serve
as
reliable
markers
need
be
examined.
Diabetic
mellitus
(DM)
a
significant
factor
for
this
malignancy
can
both
cause
consequence
PC.
Typically,
DM
caused
by
known
new-onset,
pancreatogenic,
pancreoprivic,
or
cancer-related
diabetes
(PCRD).
Although
PCRD
quite
distinct
from
type
2
(T2DM),
there
currently
biomarkers
differentiate
T2DM.
To
identify
such
biomarkers,
better
understanding
mechanisms
mediating
essential.
end,
has
been
growing
research
interest
recent
years
elucidate
role
tumour-derived
exosomes
their
cargo
pathogenesis
PCRD.
Exosomes
derived
tumours
recognized
specificity
because
they
reflect
characteristics
parent
cells
important
intercellular
communication.
Their
consists
proteins,
lipids,
nucleic
acids,
which
transferred
alter
behaviour
recipient
cells.
This
review
provides
concise
overview
current
knowledge
regarding
discusses
potential
areas
worthy
further
study.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(3), P. 654 - 654
Published: Feb. 3, 2024
Small
extracellular
vesicles
(sEVs)
contain
lipids,
proteins
and
nucleic
acids,
which
often
resemble
their
cells
of
origin.
Therefore,
plasma
sEVs
are
considered
valuable
resources
for
cancer
biomarker
development.
However,
previous
efforts
have
been
largely
focused
on
the
level
miRNAs
in
sEVs,
post-translational
modifications
sEV
proteins,
such
as
arginine
methylation,
not
explored.
Protein
a
relatively
stable
modification,
is
newly
described
molecular
feature
PDAC.
The
present
study
examined
methylation
patterns
derived
from
patients
with
early-stage
PDAC
(n
=
23)
matched
controls.
By
utilizing
methylation-specific
antibodies
western
blotting,
we
found
that
protein
altered
Specifically,
observed
reduction
symmetric
dimethyl
(SDMA)
early-
late-stage
Importantly,
immunoprecipitation
followed
by
proteomics
analysis
identified
number
arginine-methylated
exclusively
These
results
indicate
potential
indicators
PDAC,
new
concept
meriting
further
investigation.
DMW - Deutsche Medizinische Wochenschrift,
Journal Year:
2023,
Volume and Issue:
148(05), P. 246 - 252
Published: Feb. 27, 2023
Zusammenfassung
Das
Pankreaskarzinom
nimmt
in
Deutschland
stetig
an
Häufigkeit
zu
und
stellt
aktuell
die
dritthäufigste
tumorbedingte
Todesursache
dar.
Voraussichtlich
rückt
es
bis
2030
auf
den
2.
Platz
2050
1.
der
krebsbedingten
Todesfälle
vor.
Pankreasadenokarzinom
wird
überwiegenden
Mehrzahl
Fälle
spät
diagnostiziert
5-Jahre-Überlebensrate
liegt
nach
wie
vor
bei
nur
10
%.
Zu
beeinflussbaren
Risikofaktoren
zählen
das
Tabakrauchen,
ein
übermäßiges
Körpergewicht,
Alkoholkonsum,
Typ-2-Diabetes
metabolische
Syndrom.
Der
Rauchstopp
gewollte
Gewichtsabnahme
(bei
Adipositas)
können
Pankreaskrebsrisiko
um
etwa
50
%
reduzieren.
Zudem
ist
Früherkennung
des
sporadischen
Pankreaskarzinoms
im
Stadium
IA
–
nun
mit
einem
5-Jahre-Überleben
von
80
Menschen
über
neu
diagnostiziertem
Diabetes
eine
realistische
Perspektive
geworden.
Aktuelle
Entwicklungen
hierzu
werden
kurz
beschrieben.
